ShineVia Intelligent Completes Series A Financing to Advance Its Global Leadership in Specialized Optical Imaging Platform

VCBeat has learned that Shinevia (Jinan Microscopic Intelligent Technology Co., Ltd.), an internationally leading company specializing in special light imaging, has recently completed a Series A financing round worth hundreds of millions of yuan. The round was co-led by Jinan Hi-Tech Finance Investment and Licheng Zhongtai Tongxin, with continued participation from existing and new shareholders. The funds will be used for the research and development, production, market promotion of new product pipelines, as well as team expansion.

ShineVia was established on June 29, 2017, in the High-Tech Zone of Jinan City, Shandong Province. It has currently set up management and operation centers, R&D centers, and production centers in Shanghai, Hangzhou, and Liuyang, respectively. The company has been recognized as a High-Tech Enterprise in Shandong Province, a Specialized, Refined, Differential, and Innovative (SRDI) Enterprise in Shandong Province, an SRDI Enterprise in Jinan City, a Gazelle Enterprise in Jinan City, and a High-Tech Enterprise in Hunan Province.

With the vision of “becoming a creator of specialized optical technologies that lead the industry, continuously providing innovative diagnostic and therapeutic tools for healthcare professionals, and safeguarding human health,” the company has partnered with hundreds of tertiary hospitals and nearly one thousand secondary hospitals across China to promote its products, supplying clinicians with fluorescence imaging systems, ultra-high-definition endoscopic equipment, and a comprehensive range of surgical instruments.

The company possesses a globally leading specialized optical imaging technology platform, has been granted over 100 patents, and ranks among the top three worldwide in patent search volume within its niche sector. Its independently developed, pioneering picomolar-level ultra-high-sensitivity image detector is globally leading, and the company holds the invention patent for the world’s fifth fluorescent contrast agent.

Currently, the company has successfully commercialized multiple products and obtained over 20 Class II medical device registration certificates. Its product portfolio covers departments including thyroid surgery, breast surgery, hepatobiliary surgery, thoracic surgery, gastrointestinal surgery, gynecology, and lymphatic surgery, establishing a closed-loop business model of “equipment + consumables.” ShineVia is one of the few companies worldwide that has mastered autofluorescence imaging technology and successfully achieved its commercialization.

Prior to this round of financing, Shinevia had completed three rounds of funding, with investors including Luxin Venture Capital, GT Venture Capital, Zhenghai Investment, Linglong Fund, and Shiyue Capital.

For this round of financing,Yang Cong, Founder of ShineviaStatement: I am deeply grateful to our new shareholders for their recognition of the company, and equally thankful to our existing shareholders for their unwavering support. This round of financing coincided with the abrupt end of the pandemic era and the sudden onset of the post-pandemic period. During this time, a dense array of policies targeting the healthcare industry were introduced in rapid succession. Traditional experience fell silent in the face of these “black swan” events, while diverse viewpoints remained divided and inconclusive. In an era where “the only constant is change,” our partners have still firmly chosen Shinevia. I believe this decision reflects not only their acknowledgment of our track record of consistently exceeding investor expectations, but also their appreciation of our corporate character in navigating volatility: maintaining humility while making agile decisions; adhering to fundamental principles while innovating strategically.In fact, the conclusion of each financing round marks the beginning of new challenges for me, adding to the pressure in my heart and the weight on my shoulders. In the grand flow of history, we are but insignificant, unable to alter the direction of the times. However, when I reflect on our capacity to save one more patient, help one more family, and contribute a little more happiness to society, I am filled with a sense of mission that empowers me to move forward with courage and determination. As Winston Churchill said, “Success is not final, failure is not fatal: it is the courage to continue that counts.” It is a privilege to work in the healthcare industry and to receive the support and assistance of our partners. This has instilled in Shinevia the conviction to “establish a moral compass for the world and secure the well-being of the people.” The road ahead is long and arduous, but perseverance will surely lead us to our destination.

Yang Yongbo, General Manager of JINAN HI-TECH FINACE INVESTMENTStatement: As a breakthrough technology in the field of novel medical imaging, fluorescence molecular imaging represents one of the key directions for the advancement of medical imaging. Leveraging its fluorescence technology platform, the company is dedicated to developing fluorescence-based products for surgical applications in thyroid, breast, hepatobiliary, and other specialties. It has successfully commercialized multiple domestically leading products and achieved numerous technological breakthroughs. The company’s team features complementary expertise, possesses a deep understanding of the actual needs of hospital end-users, and follows a clear industrialization strategy. We are honored to participate in this round of financing for Shinevia. Moving forward, we will continue to support the enterprise, empowering it to enhance efficiency and drive growth.

Chen Zhe, representative appointed by Licheng Zhongtai Tongxin FundIt is indicated that as the impact of the pandemic gradually recedes, the focus of procurement within the healthcare system has shifted from emergency pandemic-related supplies to general medical supplies. Departments significantly affected by the pandemic, such as respiratory and gastroenterology departments, have resumed normal procurement levels for related products, laying a solid foundation for the growth of the domestic endoscope market. As the world’s second-largest medical device market, China’s medical device sector holds substantial potential for future development. Shinevia’s R&D system, which is “guided by clinical needs, driven by product innovation and process optimization, and supported by industry technology,” is well-positioned to capitalize on the trend toward the “consumabilization” of endoscopes. The company has established strong competitive advantages and a leading industry position in the domestic market for special light imaging technologies.

Jinan Hi-Tech Finance Investment is a wholly state-owned enterprise approved by the Administrative Committee of Jinan High-tech Industrial Development Zone, integrating equity investment, capital operation, and financial services. With a registered capital of RMB 3 billion, total assets exceeding RMB 13 billion, and a total investment amounting to RMB 6.5 billion, the company holds stakes in over 40 enterprises. It has achieved an AA+ issuer credit rating. Its investment portfolio spans biopharmaceuticals, aerospace information, intelligent manufacturing, and information technology. To date, seven portfolio companies have completed initial public offerings (IPOs), with several others preparing for IPOs.

Zhongtai Capital was established in May 2010, with a registered capital of RMB 2.22 billion and paid-in capital of RMB 1.996 billion. As a specialized capital management entity under Zhongtai Securities Co., Ltd. focusing on private equity fund operations, it manages Zhongtai Securities’ domestic and overseas private investment fund businesses and has grown into one of China’s leading private equity investment management firms. The firm currently maintains fund management teams in Jinan, Beijing, Shenzhen, and Shanghai, overseeing a diverse range of funds including RMB-denominated corporate equity investment funds, funds of funds (FOFs), and merger and acquisition (M&A) funds.